FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington.	D C	20540
wasnington.	D.C.	20549

STATEMENT	OF CHANGES	IN BENEFICIAL	OWNERSHIP

OMB APPROVAL									
OMB Number: 3235-0287									
Estimated average burden									
hours per response:	0.5								

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934

						01 00	CLIOIT	30(11) 01 1110	mive Stille		mparty 7 tot	01 104							
1. Name and Address of Reporting Person* GOEDDEL DAVID V																ble)	g Perso	10% Ov	vner
(Last) (First) (Middle) C/O TENAYA THERAPEUTICS, INC. 171 OYSTER POINT BLVD., 5TH FLR						3. Date of Earliest Transaction (Month/Day/Year) 08/03/2021									Officer ((below)	give title		Other (s below)	specify
(Street) SOUTH SAN FRANCISCO CA 94080			4	4. If Amendment, Date of Original Filed (Month/Day/Year)								Line)	6. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person						
(City)	?)	State)	(Zip)																
1. Title of Security (Instr. 3) 2. Tran			sactio			quired, Disposed of, or Benefic 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 a			() or	5. Amount of		Form: Direct (D) or Indirect		7. Nature of Indirect Beneficial Ownership					
				(, , , , , , , , , , , , , , , , , , ,		Code	v	Amount (A) or (D) Pri		Price	Reported Transaction(s) (Instr. 3 and 4)		(1)		Instr. 4)				
Common Stock			08/0)3/20	3/2021		С		4,389,2	282	A	\$0.00	4,414,720		I		See Footnote ⁽¹⁾		
Common Stock			08/0)3/20	3/2021					4,956,842		A	\$0.00	4,985,570				See Footnote ⁽²⁾	
			Table II					ties Acq warrants							wned				
1. Title of Derivative Security (Instr. 3) 2. Conversion of Exercity Price of Derivative Security		3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Da if any (Month/Day/)	ate, T	4. Transaction Code (Instr. 8)		5. Number of Derivative		6. Date Exercisable Expiration Date (Month/Day/Year)		е	able and 7. Title and Am		derlying curity	unt of 8. Price of Derivative		per of ve es ially	Ownership Form: Direct (D) or Indirect (I) (Instr. 4	Beneficial Ownership (Instr. 4)
				c	Code	v	(A)	(D)	Date Exercisa		Expiration Date	Title	Ni	nount or umber of nares		Transact (Instr. 4)			
Series A Preferred Stock	\$0.00 ⁽³⁾	08/03/2021			С			3,727,742	(3)		(3)	Comn		727,742	(3)	0		I	See Footnote ⁽¹⁾
Series A Preferred Stock	\$0.00 ⁽³⁾	08/03/2021			С			4,209,755	(3)		(3)	Comn		209,755	(3)	0		I	See Footnote ⁽²⁾
Series B Preferred Stock	\$0.00 ⁽³⁾	08/03/2021			С			472,659	(3)		(3)	Comn		172,659	(3)	a		I	See Footnote ⁽¹⁾
Series B Preferred Stock	\$0.00 ⁽³⁾	08/03/2021			С			533,781	(3)		(3)	Comn		533,781	(3)	0		I	See Footnote ⁽²⁾
Series C Preferred Stock	\$0.00 ⁽³⁾	08/03/2021			С			188,881	(3)		(3)	Comn		.88,881	(3)	0		I	See Footnote ⁽¹⁾
Series C Preferred	\$0.00 ⁽³⁾	08/03/2021			С			213,306	(3)		(3)	Comn		213,306	(3)	0		I	See Footnote ⁽²⁾

Explanation of Responses:

- 1. The securities are directly held by The Column Group III, LP ("TCG III LP"). The Column Group III GP, LP ("TCG III GP") is the general partner of TCG III LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing partners of TCG III GP are David Goeddel, a member of the Issuer's board of directors, Peter Svennilson and Tim Kutzkey (collectively, the "Managing Partners"). The Managing Partners may be deemed to share voting and investment power with respect to such shares. TCG III GP and each of the Managing Partners disclaim beneficial ownership of these shares, except to the extent of their respective pecuniary interest in such shares.
- 2. These securities are directly held by The Column Group III-A, LP ("TCG III-A LP"). TCG III GP is the general partner of TCG III-A LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing partners of TCG III GP are the Managing Partners. The Managing Partners may be deemed to share voting and investment power with respect to such shares. TCG III GP and each of the Managing Partners disclaim beneficial ownership of these shares, except to the extent of their respective pecuniary interest in such shares.
- 3. Each share of Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock automatically converted into one share of common stock immediately prior to the completion of the Issuer's initial public offering, and had no expiration date.

Remarks:

/s/ Leone Patterson Attorney-in-Fact for David V. Goeddel

08/03/2021

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.